文献速递妇科

新诊断晚期卵巢癌患者接受尼拉帕利对比安慰剂治疗的健康相关生活质量:3期随机PRIMA/ENGOT-OV26/GOG-3012试验结果

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
PubMed 文献 · Gynecol Oncol · 2024-02-06

PRIMA/ENGOT-OV26/GOG-3012试验纳入新诊断晚期卵巢癌对一线铂类化疗有应答的患者,按2:1随机接受尼拉帕利或安慰剂每日一次维持治疗。患者报告结局量表依从性超过80%,尼拉帕利组腹部/胃肠道症状及恶心呕吐、食欲减退、便秘评分较安慰剂组更差,除便秘外这些差异随时间消退,总体健康相关生活质量无恶化。

要点

  • 尼拉帕利组腹部/胃肠道症状及恶心呕吐、食欲减退、便秘评分高于安慰剂组,除便秘外差异随时间消退。
  • EORTC QLQ-C30总体健康状况/生活质量及FOSI总体评分随时间未见下降。
  • 患者未自报疲劳、头痛、失眠或腹痛较基线恶化。

核心结论

  • 尽管早期胃肠道症状有所增加且多为一过性,接受尼拉帕利一线维持治疗的卵巢癌患者总体健康相关生活质量未见恶化。

研究设计与样本

  • PRIMA/ENGOT-OV26/GOG-3012(NCT02655016)为3期随机试验,纳入新诊断晚期卵巢癌对一线铂类化疗有应答的患者。
  • 患者按2:1随机接受尼拉帕利或安慰剂每日一次,28天为一周期,直至疾病进展、不可耐受毒性或死亡。
  • 健康相关生活质量为预设次要终点,采用EORTC QLQ-C30、EORTC QLQ-OV28、FOSI和EQ-5D-5L问卷评估。
  • 评估在基线及第1周期第1天起每8周(±7天)至56周,此后每12周(±7天)收集。
  • 尼拉帕利组487例,安慰剂组246例。

主要发现

  • 所有量表在所有周期的患者报告结局依从性均超过80%。
  • EORTC QLQ-C30总体健康状况/生活质量及FOSI总体评分随时间未见下降。
  • EORTC QLQ-OV28腹部/胃肠道症状及EORTC QLQ-C30恶心呕吐、食欲减退、便秘评分尼拉帕利组高于安慰剂组(症状更差)。
  • 除便秘外,上述差异随时间消退。
  • 患者未自报疲劳、头痛、失眠或腹痛较基线恶化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. METHODS: PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled patients with newly diagnosed advanced OC who responded to first-line platinum-based chemotherapy. Patients were randomized (2:1) to niraparib or placebo once daily in 28-day cycles until disease progression, intolerable toxicity, or death. HRQoL was assessed as a prespecified secondary end point using patient-reported responses to the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30), the EORTC QLQ Ovarian Cancer Module (EORTC QLQ-OV28), the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI), and EQ-5D-5L questionnaires. Assessments were collected at baseline and every 8 weeks (±7 days) for 56 weeks, beginning on cycle 1/day 1, then every 12 weeks (±7 days) thereafter while the patient received study treatment. RESULTS: Among trial participants (niraparib, n = 487; placebo, n = 246), PRO adherence exceeded 80% for all instruments across all cycles. Patients reported no decline over time in HRQoL measured via EORTC QLQ-C30 Global Health Status/QoL and FOSI overall scores. Scores for abdominal/gastrointestinal symptoms (EORTC QLQ-OV28) and nausea and vomiting, appetite loss, and constipation (EORTC QLQ-C30) were higher (worse symptoms) in niraparib-treated patients than placebo-treated patients; except for constipation, these differences resolved over time. Patients did not self-report any worsening from baseline of fatigue, headache, insomnia, or abdominal pain on questionnaires. CONCLUSIONS: Despite some early, largely transient increases in gastrointestinal symptoms, patients with OC treated with niraparib first-line maintenance therapy reported no worsening in overall HRQoL.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Pothuri B, Han S, Chase DM, et al. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024. PMID: 38325276. doi:10.1016/j.ygyno.2024.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。